Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | AHR | P35869 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NMT2 | O60551 | 1/20 | 0.48 |
| ▸ | NMT1 | P30419 | 1/20 | 0.48 |
| ▸ | CDC25B | P30305 | 4/20 | 0.47 |
| ▸ | GABRP | O00591 | 1/20 | 0.47 |
| ▸ | GABRD | O14764 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3460446 | 0.87 | MAOB (0.56) | KDM4EAHRMAOBAKR1B1ALDH1A1 | |
| SCHEMBL31353116 | 0.84 | MAOB (0.53) | KDM4EAHRMAOBAKR1B1ALDH1A1 | |
| SCHEMBL28368214 | 0.84 | MAOB (0.53) | KDM4EAHRMAOBAKR1B1ALDH1A1 | |
| SCHEMBL9955893 | 0.84 | MAOB (0.60) | KDM4EAHRMAOBAKR1B1ALDH1A1 | |
| SCHEMBL8440469 | 0.84 | MAOB (0.53) | KDM4EAHRMAOBAKR1B1ALDH1A1 | |
| SCHEMBL16693136 | 0.84 | MAOB (0.53) | KDM4EAHRMAOBAKR1B1ALDH1A1 | |
| SCHEMBL27878925 | 0.83 | KDM4E (0.53) | KDM4EMAOBALDH1A1HSD17B10ATM | |
| SCHEMBL4105762 | 0.83 | NMT2 (0.54) | KDM4EAHRMAOBAKR1B1ALDH1A1 | |
| SCHEMBL4251548 | 0.83 | AKR1B1 (0.56) | KDM4EAHRMAOBAKR1B1ALDH1A1 | |
| SCHEMBL10955268 | 0.82 | MAOB (0.51) | KDM4EAHRMAOBAKR1B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110770233-B | Fused bicyclic compound and application thereof in medicine | 广东东阳光药业有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-110770233-A | Fused bicyclic compound and application thereof in medicine | 广东东阳光药业有限公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20140249143-A1 | Compounds And Methods For Enhancing Innate Immune Responses | GLAXOSMITHKLINE LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249143-A1 | Compounds And Methods For Enhancing Innate Immune Responses | GLAXOSMITHKLINE LLC (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2013059559-A2 | COMPOUNDS AND METHODS FOR ENHANCING INNATE IMMUNE RESPONSES | GLAXOSMITHKLINE LLC (US) | 2013-04-25 | — | — | WO | disclosed |
| US-6140331-A | FOR TREATING ANXIETY DISORDERS, DEPRESSION, PSYCHOSIS, IMPULSE CONTROL DISORDERS, ALCOHOL ABUSE, ISCHAEMIC DISEASES, CARDIOVASCULAR DISORDERS, SIDE EFFECTS INDUCED BY CONVENTIONAL ANTIPSYCHOTIC AGENTS AND SENILE DEMENTIA | H. LUNDBECK A/S (DK) | 2000-10-31 | — | — | US | disclosed |
| EP-0673375-B1 | FUSED BENZO COMPOUNDS | LUNDBECK & CO AS H (DK) | 1999-02-24 | — | — | EP | disclosed |
| US-5753661-A | TREATMENT OF NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | H. LUNDBECK A/S (DK) | 1998-05-19 | — | — | US | disclosed |
| EP-0673375-A1 | FUSED BENZO COMPOUNDS | H. LUNDBECK A/S (DK) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994013659-A1 | FUSED BENZO COMPOUNDS | H. LUNDBECK A/S (DK) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249143-A1 | Compounds And Methods For Enhancing Innate Immune Responses | MYD88, IRF3, MAVS | KDM4E 3366/4885AHR 1843/4885MAOB 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.